| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_63d88002a3831554f8ddd51bd2565f6e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2835
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2845
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 |
| filingDate |
2018-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b6afbbc6c506abbb4d0e7797f2be0e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93f03c16ed7bf0a9827e4dcd2aeda6ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8efbeb26e61ca1eb135b67cb90b647d5 |
| publicationDate |
2018-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018344748-A1 |
| titleOfInvention |
Methods and compositions for preventing or treating chronic inflammatory diseases |
| abstract |
Described are methods of treating or preventing an inflammatory disease or condition caused by excessive expression, secretion, or concentration of alpha synuclein. The methods comprise administering compositions that reduce the effective concentration of alpha-synuclein present in the surrounding tissues. In addition, the invention encompasses methods of inhibiting alpha-synuclein interaction with CD11b, comprising administering an agent that binds to alpha-synuclein to prevent binding productively to the integrin CD11b, or administering an active agent that interacts with CD11b on an immune cell to prevent alpha-synuclein from directing chemotaxis of that cell. In addition, the invention discloses a method of identifying an individual with a condition amenable to treatment targeting alpha-synuclein CD11b interaction. |
| priorityDate |
2017-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |